Cohance Lifesciences Limited — Others, 12-11-2024: Appointment

Suven Pharmaceuticals has announced a board meeting to approve its financial results for the quarter and half-year ended September 30, 2024. The company reported revenue of ₹258 crore for Q2, reflecting a 12% year-on-year growth, driven largely by its Pharma CDMO division, which saw a 40% increase. EBITDA margins improved to 43.3%, indicating strong operational efficiency. Additionally, the board approved the appointment of Mr. Jai Shankar Krishnan and Mr. Vinod Padikkal as independent and non-executive directors, respectively, pending shareholder approval. This strategic enhancement in leadership could benefit investor sentiment by confirming governance stability as the company navigates its growth initiatives.